Lytix Biopharma ASA (OSL:LYTIX)
Norway · Delayed Price · Currency is NOK 9.48
+0.24 (2.60%)
Jul 15, 2026, 4:15 PM CET
Lytix Biopharma ASA Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | - | - | 11.13 | 3.99 | 11.03 | 19.31 |
| - | - | 11.13 | 3.99 | 11.03 | 19.31 | |
Revenue Growth (YoY) | - | - | 178.98% | -63.82% | -42.86% | 373.91% |
Gross Profit | - | - | 11.13 | 3.99 | 11.03 | 19.31 |
Selling, General & Admin | 34.84 | 32.62 | 22.59 | 24.34 | 20.41 | 31.1 |
Research & Development | 21.78 | 13.8 | 72.57 | 63.17 | 45.61 | 23.74 |
Other Operating Expenses | 19.78 | 16.6 | 10.96 | 12.3 | 9.76 | 12.01 |
Operating Expenses | 77.39 | 64.03 | 107.03 | 100.78 | 76.7 | 67.29 |
Operating Income | -77.39 | -64.03 | -95.9 | -96.79 | -65.67 | -47.99 |
Interest Expense | -0.21 | -0.21 | -0.13 | -0.06 | -0.15 | -0.07 |
Interest & Investment Income | 2.67 | 2.33 | 1.51 | 2.35 | 1.41 | 0.14 |
Currency Exchange Gain (Loss) | 0.17 | 0.17 | -0.08 | 4.01 | 7.72 | -0.17 |
Other Non Operating Income (Expenses) | 1.76 | 1.76 | 0.33 | 2.59 | 0.61 | 0.01 |
EBT Excluding Unusual Items | -73 | -59.98 | -94.27 | -87.9 | -56.07 | -48.08 |
Pretax Income | -73 | -59.98 | -94.27 | -87.9 | -56.07 | -48.08 |
Earnings From Continuing Operations | -73 | -59.98 | -94.27 | -87.9 | -56.07 | -48.08 |
Net Income | -73 | -59.98 | -94.27 | -87.9 | -56.07 | -48.08 |
Net Income to Common | -73 | -59.98 | -94.27 | -87.9 | -56.07 | -48.08 |
Shares Outstanding (Basic) | - | 68 | 54 | 40 | 40 | 33 |
Shares Outstanding (Diluted) | - | 68 | 54 | 40 | 40 | 33 |
Shares Change (YoY) | - | 26.05% | 35.05% | 1.01% | 19.50% | 26.57% |
EPS (Basic) | - | -0.88 | -1.74 | -2.19 | -1.41 | -1.45 |
EPS (Diluted) | - | -0.88 | -1.74 | -2.19 | -1.41 | -1.45 |
Free Cash Flow | -75.74 | -59.85 | -70.37 | -96.02 | -52.78 | -44.61 |
Free Cash Flow Per Share | - | -0.88 | -1.30 | -2.40 | -1.33 | -1.34 |
Gross Margin | - | - | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | - | - | -861.29% | -2425.08% | -595.28% | -248.54% |
Profit Margin | - | - | -846.64% | -2202.38% | -508.29% | -249.02% |
Free Cash Flow Margin | - | - | -632.05% | -2405.86% | -478.47% | -231.04% |
EBITDA | -77.36 | -63.99 | -95.83 | -96.72 | -65.64 | -47.53 |
EBITDA Margin | - | - | - | - | - | -246.20% |
D&A For EBITDA | 0.03 | 0.04 | 0.07 | 0.06 | 0.03 | 0.45 |
EBIT | -77.39 | -64.03 | -95.9 | -96.79 | -65.67 | -47.99 |
EBIT Margin | - | - | - | - | - | -248.54% |
Revenue as Reported | - | - | 11.13 | 3.99 | 11.03 | 19.5 |